Table 2 The hazard ratio of the duration of using metformin and sulfonylurea on incident hard CVD events and CVD mortality.

Model	Exposure (Medication time in years)	Cox model			Fine-Gray model
Model	Exposure (Medication time in years)	Hazard ratio adjusted	95% CI	P value	SHR	95% CI	p-value
Incident hard CVD events
1	Metformin	0.88	0.82,0.95	0.001	0.90	0.82,0.95	0.001
	Sulfonylurea	0.94	0.87,1.01	0.11	0.96	0.89,1.02	0.15
	Sulfonylurea + Metformin	0.87	0.80,0.95	0.001	0.89	0.82,0.97	0.001
2	Metformin	0.89	0.85,0.94	0.001	0.91	0.87,0.95	0.006
	Sulfonylurea	0.95	0.90,1.01	0.085	0.97	0.94,1.01	0.18
	Sulfonylurea + Metformin	0.88	0.81,0.95	0.001	0.91	0.88,0.95	0.001
3	Metformin	0.93	0.90,0.97	0.009	0.94	0.90,0.99	0.007
	Sulfonylurea	0.96	0.94,0.99	0.043	0.98	0.91,1.05	0.11
	Sulfonylurea + Metformin	0.92	0.88,0.97	0.001	0.93	0.89,0.97	0.005
	Hypertension medication	0.97	0.96,0.99	0.029	0.97	0.95,0.99	0.035
	Statin	0.96	0.94,0.99	0.021	0.97	0.95,0.99	0.029
	aspirin	0.97	0.96,0.99	0.032	0.98	0.97,0.99	0.049
CVD mortality
1	Metformin	0.89	0.87,0.94	0.001	0.91	0.86,0.96	0.001
	Sulfonylurea	0.94	0.88,0.99	0.028	0.95	0.92,0.99	0.048
	Sulfonylurea + Metformin	0.88	0.82,0.95	0.001	0.9	0.84,0.97	0.001
2	Metformin	0.90	0.85,0.98	0.006	0.92	0.87,0.98	0.015
	Sulfonylurea	0.95	0.89,1.02	0.087	0.96	0.90,1.03	0.089
	Sulfonylurea + Metformin	0.87	0.80,0.95	0.001	0.89	0.83,0.96	0.001
3	Metformin	0.94	0.91,0.98	0.006	0.96	0.94,0.99	0.012
	Sulfonylurea	0.96	0.94,0.99	0.049	0.97	0.96,0.99	0.049
	Sulfonylurea + Metformin	0.93	0.89,0.98	0.001	0.95	0.93,0.97	0.001
	Anti-hypertensive drugs	0.96	0.93,0.99	0.025	0.96	0.93,0.99	0.042
	Statin	0.95	0.93,0.98	0.006	0.96	0.93.,0.98	0.011
	aspirin	0.96	0.94,0.99	0.012	0.97	0.94,0.99	0.045

Model 1: Crude.
Model 2: Adjusted for Mean of age and Mean of FBS at follow-up.
Model 3: Adjusted for Mean of age, FBS, HDL, LDL, TG, waist, physical activity, statin use, aspirin use, anti-hypertensive, educational level, creatinine, Sex, smoking and Systolic and diastolic blood pressure (mmHg) at follow-up period.
CPH model was used in model 1, 2 and 3.
Fine-Gray model was used to estimate the competing risk effect.

Search